EPISODE · Jun 30, 2026 · 21 MIN
GLP-1s, Peptides, and the Line Between Medicine and Mischief
from Wicklow Strength and Fitness
Two things are happening in the fitness industry at the same time. One is genuinely good news for a lot of people. One is genuinely bad news for a lot of people. And the public conversation has merged them into one big sweaty blob of "gym people doing drugs."In this episode of the Wicklow Strength and Fitness Podcast, we draw a clear line between them.On one side: GLP-1 medications (Ozempic, Wegovy, Mounjaro). The most significant intervention in weight management in our lifetimes, possibly ever. Prescribed by doctors. Backed by huge clinical trials. Changing what is possible for the right person with the right plan.On the other side: unregulated peptides being sold by personal trainers in gym back rooms. No prescription. No medical oversight. No accountability when it goes wrong. Australia's Therapeutic Goods Administration issued a formal safety alert about exactly this in April 2026, citing hospitalisations from products like BPC-157.We cover:What GLP-1s actually are, and the honest case for themWhat "the right person with a long term exit plan" actually looks likeWhy the fitness industry has reacted badly to GLP-1s (and what that tells you)The pattern of harm we are seeing with trainer-sold peptidesA rule of thumb you can apply to anyone offering to put something in your body in a fitness contextThis is for anyone considering a GLP-1, anyone already on one, anyone whose trainer has ever offered them anything in a vial, and anyone trying to make sense of the most confusing moment the fitness industry has had in years.If you are local to Wicklow Town and want a coach who will work alongside whatever your doctor is doing, book a free consultation here: https://api.grow.pushpress.com/widget/bookings/intro
NOW PLAYING
GLP-1s, Peptides, and the Line Between Medicine and Mischief
No transcript for this episode yet
Similar Episodes
Mar 26, 2026 ·1m
Mar 19, 2026 ·34m
Feb 18, 2026 ·11m
Feb 11, 2026 ·45m